Alexander A. Fitzpatrick - 18 Feb 2022 Form 4 Insider Report for Evofem Biosciences, Inc. (EVFM)

Role
General Counsel and Secretary
Signature
/s/ Justin J. File, attorney-in-fact
Issuer symbol
EVFM
Transactions as of
18 Feb 2022
Transactions value $
$0
Form type
4
Filing time
23 Feb 2022, 15:08:06 UTC
Previous filing
04 Jan 2022
Next filing
01 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVFM Common Stock Award $0 +300K +138.62% $0.00 516K 18 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVFM Stock option (right to buy) Award $0 +300K $0.00 300K 18 Feb 2022 Common Stock 300K $0.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.
F2 The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.